GHRP-2 (trifluoroacetate salt)
(Synonyms: D-Ala-3-(2-naphthalenyl)-D-Ala-L-Ala-L-Trp-D-Phe-L-lysinamide, Growth Hormone-Releasing Peptide 2, KP-102, Pralmorelin) 目录号 : GC45803
A neuropeptide with diverse biological activities
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
GHRP-2 is an orally bioavailable synthetic growth hormone (GH) secretagogue and an agonist of the GH secretagogue receptor (GHS-R), which is also known as the ghrelin receptor.1 It induces GH release from primary rat pituitary cells (EC50 = 1.8 nM) and binds to human hypothalamic membranes (IC50 = 16 nM).2,3 GHRP-2 increases blood GH levels in anesthetized rats (ED50 = 30 nmol/kg) and serum GH levels in conscious pigs (ED50 = 0.6 nmol/kg).2 It also increases food intake and body weight gain in rats when administered at a dose of 100 μg/kg per day.4
|1. Peroni, C.N., Hayashida, C.Y., Nascimento, N., et al. Growth hormone response to growth hormone-releasing peptide-2 in growth hormone-deficient little mice. Clinics (Sao Paulo) 67(3), 265-272 (2012).|2. Ankersen, M., Johansen, N.L., Madsen, K., et al. A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. J. Med. Chem. 41(19), 3699-3704 (1998).|3. Muccioli, G., GhÈ, C., Ghigo, M.C., et al. Specific receptors for synthetic GH secretagogues in the human brain and pituitary gland. J. Endocrinol. 157(1), 99-106 (1998).|4. Granado, M., Priego, T., MartÍn, A.I., et al. Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am. J. Physiol. Endocrinol. Metab. 288(3), E486-E492 (2005).
| Cas No. | N/A | SDF | |
| 别名 | D-Ala-3-(2-naphthalenyl)-D-Ala-L-Ala-L-Trp-D-Phe-L-lysinamide, Growth Hormone-Releasing Peptide 2, KP-102, Pralmorelin | ||
| Canonical SMILES | C[C@@H](N)C(N[C@H](CC1=CC=C(C=CC=C2)C2=C1)C(N[C@@H](C)C(N[C@@H](CC3=CNC4=C3C=CC=C4)C(N[C@H](CC5=CC=CC=C5)C(N[C@@H](CCCCN)C(N)=O)=O)=O)=O)=O)=O.FC(F)(C(O)=O)F | ||
| 分子式 | C45H55N9O6.CF3COOH | 分子量 | 932 |
| 溶解度 | Water: 1 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.073 mL | 5.3648 mL | 10.7296 mL |
| 5 mM | 0.2146 mL | 1.073 mL | 2.1459 mL |
| 10 mM | 0.1073 mL | 0.5365 mL | 1.073 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。